Augmentation_NN of_IN the_DT Lipopolysaccharide-Neutralizing_NP Activities_NP of_IN Human_NP Cathelicidin_NP CAP18/LL-37-Derived_NP Antimicrobial_NP Peptides_NP by_IN Replacement_NP with_IN Hydrophobic_NP and_CC Cationic_NP Amino_NP Acid_NP Residues_NP Mammalian_NP myeloid_JJ and_CC epithelial_JJ cells_NNS express_VBP various_JJ peptide_NN antibiotics_NNS (_( such_JJ as_IN defensins_NNS and_CC cathelicidins_NNS )_) that_WDT contribute_VBP to_TO the_DT innate_JJ host_NN defense_NN against_IN invading_VBG microorganisms_NNS ._SENT Among_IN these_DT peptides_NNS ,_, human_JJ cathelicidin_NNS CAP18/LL-37_JJ (_( L1_JJ to_TO S37_NP )_) possesses_VBZ not_RB only_RB potent_JJ antibacterial_NN activity_NN against_IN gram-positive_JJ and_CC gram-negative_JJ bacteria_NNS but_CC also_RB the_DT ability_NN to_TO bind_VB to_TO gram-negative_JJ lipopolysaccharide_NN (_( LPS_NP )_) and_CC neutralize_VB its_PP$ biological_JJ activities_NNS ._SENT In_IN this_DT study_NN ,_, to_TO develop_VB peptide_NN derivatives_NNS with_IN improved_VBN LPS-neutralizing_JJ activities_NNS ,_, we_PP utilized_VBD an_DT 18-mer_JJ peptide_NN (_( K15_NP to_TO V32_NP )_) of_IN LL-37_JJ as_IN a_DT template_NN and_CC evaluated_VBD the_DT activities_NNS of_IN modified_JJ peptides_NNS by_IN using_VBG the_DT CD14+_NP murine_JJ macrophage_NN cell_NN line_NN RAW_NP 264.7_CD and_CC the_DT murine_JJ endotoxin_NN shock_NN model_NN ._SENT By_IN replacement_NN of_IN E16_NP and_CC K25_NP with_IN two_CD L_NP residues_NNS ,_, the_DT hydrophobicity_NN of_IN the_DT peptide_NN (_( 18-mer_NP LL_NP )_) was_VBD increased_VBN ,_, and_CC by_IN further_JJR replacement_NN of_IN Q22_NP ,_, D26_NP ,_, and_CC N30_NP with_IN three_CD K_NP residues_NNS ,_, the_DT cationicity_NN of_IN the_DT peptide_NN (_( 18-mer_NP LLKKK_NP )_) was_VBD enhanced_VBN ._SENT Among_IN peptide_NN derivatives_NNS ,_, 18-mer_NP LLKKK_NP displayed_VBD the_DT most_RBS powerful_JJ LPS-neutralizing_NP activity_NN :_: it_PP was_VBD most_RBS potent_JJ at_IN binding_VBG to_TO LPS_NP ,_, inhibiting_VBG the_DT interaction_NN between_IN LPS_NP and_CC LPS-binding_NP protein_NN ,_, and_CC attaching_VBG to_TO the_DT CD14_NP molecule_NN ,_, thereby_RB suppressing_VBG the_DT binding_NN of_IN LPS_NP to_TO CD14+_NP cells_NNS and_CC attenuating_VBG production_NN of_IN tumor_NN necrosis_NN factor_NN alpha_NN (_( TNF-alpha_NP )_) by_IN these_DT cells_NNS ._SENT Furthermore_RB ,_, in_IN the_DT murine_JJ endotoxin_NN shock_NN model_NN ,_, 18-mer_NP LLKKK_NP most_RBS effectively_RB suppressed_VBN LPS-induced_NP TNF-alpha_NP production_NN and_CC protected_JJ mice_NNS from_IN lethal_JJ endotoxin_NN shock_NN ._SENT Together_RB ,_, these_DT observations_NNS indicate_VBP that_IN the_DT LPS-neutralizing_NP activities_NNS of_IN the_DT amphipathic_JJ human_JJ CAP18/LL-37-derived_JJ 18-mer_JJ peptide_NN can_MD be_VB augmented_VBN by_IN modifying_VBG its_PP$ hydrophobicity_NN and_CC cationicity_NN ,_, and_CC that_IN 18-mer_NP LLKKK_NP is_VBZ the_DT most_RBS potent_JJ of_IN the_DT peptide_NN derivatives_NNS ,_, with_IN therapeutic_JJ potential_NN for_IN gram-negative_JJ bacterial_JJ endotoxin_NN shock_NN ._SENT Peptide_NN antibiotics_NNS exhibit_VBP potent_JJ antimicrobial_JJ activities_NNS against_IN both_DT gram-positive_JJ and_CC gram-negative_JJ bacteria_NNS ,_, fungi_NNS ,_, and_CC viruses_NNS ,_, and_CC they_PP form_VBP one_CD group_NN of_IN effector_NN components_NNS in_IN the_DT innate_JJ host_NN defense_NN system_NN ._SENT The_DT peptide-based_JJ defense_NN in_IN mammals_NNS against_IN invading_VBG microbes_NNS relies_VBZ on_IN two_CD evolutionarily_RB distinct_JJ groups_NNS of_IN antimicrobial_JJ peptides_NNS ,_, defensins_NNS and_CC cathelicidins_NNS ,_, which_WDT have_VBP been_VBN identified_VBN in_IN several_JJ epithelial_JJ tissues_NNS and_CC in_IN the_DT granules_NNS of_IN phagocytes_NNS (_( ,_, ,_, -_: ,_, ,_, ,_, )_) ._SENT Defensins_NNS contain_VBP six_CD conserved_VBN cysteine_NN residues_NNS in_IN their_PP$ sequences_NNS and_CC exhibit_VB characteristic_JJ beta-sheet_NN structures_NNS stabilized_VBN by_IN three_CD intramolecular_JJ disulfide_NN bonds_NNS ._SENT In_IN contrast_NN ,_, cathelicidins_NNS are_VBP characterized_VBN by_IN highly_RB conserved_VBN cathelin-like_JJ prosequences_NNS and_CC variable_JJ carboxyl-terminal_JJ sequences_NNS that_WDT correspond_VBP to_TO the_DT mature_JJ antibacterial_NN peptides_NNS ._SENT About_RB 30_CD cathelicidin_NN members_NNS from_IN various_JJ mammalian_JJ species_NNS have_VBP been_VBN identified_VBN ;_: however_RB ,_, only_RB one_CD cathelicidin_NN ,_, hCAP18_JJ (_( human_JJ cationic_JJ antibacterial_NN protein_NN of_IN 18_CD kDa_NNS )_) ,_, has_VBZ been_VBN found_VBN in_IN humans_NNS ,_, and_CC its_PP$ carboxyl-terminal_JJ antibacterial_NN peptide_NN ,_, called_VBD LL-37_NP ,_, which_WDT comprises_VBZ 37_CD amino_NN acid_JJ residues_NNS (_( L1LGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES37_JJ )_) ,_, has_VBZ recently_RB been_VBN identified_VBN ._SENT In_IN addition_NN to_TO exhibiting_VBG potent_JJ antibacterial_NN activities_NNS against_IN gram-positive_JJ and_CC gram-negative_JJ bacteria_NNS ,_, peptides_NNS derived_VBN from_IN LL-37_JJ can_MD bind_VB to_TO lipopolysaccharide_VB (_( LPS_NP )_) and_CC neutralize_VB its_PP$ biological_JJ activities_NNS ._SENT LPS_NP is_VBZ a_DT major_JJ constituent_NN of_IN the_DT outer_JJ membranes_NNS of_IN gram-negative_JJ bacteria_NNS and_CC is_VBZ recognized_VBN as_IN a_DT key_JJ molecule_NN in_IN the_DT pathogenesis_NN of_IN endotoxin_NN shock_NN associated_VBN with_IN gram-negative_JJ bacterial_JJ infections_NNS ._SENT Recently_RB ,_, we_PP have_VBP shown_VBN that_IN LL-37_NP exerts_VBZ protective_JJ action_NN against_IN endotoxin_NN shock_NN by_IN blocking_VBG the_DT binding_NN of_IN LPS_NP to_TO CD14+_NP cells_NNS ,_, thereby_RB suppressing_VBG the_DT production_NN of_IN cytokines_NNS by_IN these_DT cells_NNS ._SENT Thus_RB ,_, LL-37_JJ and_CC its_PP$ related_JJ derivatives_NNS could_MD be_VB attractive_JJ candidates_NNS for_IN therapeutic_JJ agents_NNS that_WDT can_MD be_VB used_VBN for_IN endotoxin_NN shock_NN and_CC sepsis_NN caused_VBN by_IN gram-negative_JJ bacterial_JJ infections_NNS ._SENT Although_IN antibacterial_NN peptides_NNS are_VBP diverse_JJ in_IN their_PP$ sizes_NNS ,_, structures_NNS ,_, and_CC activities_NNS ,_, they_PP are_VBP mostly_RB amphipathic_JJ ,_, retaining_VBG both_DT cationic_JJ (_( positively_RB charged_VBN )_) and_CC hydrophobic_JJ faces_NNS ._SENT These_DT features_NNS facilitate_VBP interactions_NNS with_IN negatively_RB charged_VBN microbial_JJ surface_NN membranes_NNS ,_, followed_VBN by_IN insertion_NN into_IN the_DT microbial_JJ lipid_NN membrane_NN ,_, which_WDT alters_VBZ membrane_NN permeability_NN and_CC impairs_VBZ internal_JJ homeostasis_NN ._SENT Moreover_RB ,_, the_DT positively_RB charged_VBN amphipathic_JJ structures_NNS are_VBP assumed_VBN to_TO be_VB important_JJ for_IN interaction_NN with_IN a_DT negatively_RB charged_VBN amphipathic_JJ LPS_NP ._SENT Interestingly_RB ,_, secondary-structure_NN predictions_NNS indicate_VBP that_IN antibacterial_NN peptides_NNS of_IN some_DT cathelicidin_NN members_NNS ,_, such_JJ as_IN hCAP18/LL-37_JJ ,_, rabbit_NN CAP18-derived_JJ peptide_NN ,_, and_CC guinea_NN pig_NN CAP11_NP (_( cationic_JJ antibacterial_NN polypeptide_NN of_IN 11_CD kDa_NNS )_) ,_, adopt_VB an_DT alpha-helical_JJ amphipathic_JJ conformation_NN ;_: the_DT helical_JJ wheel_NN regions_NNS are_VBP clearly_RB amphipathic_JJ and_CC subtended_VBN by_IN the_DT hydrophilic_JJ (_( positively_RB charged_VBN )_) and_CC hydrophobic_JJ sectors_NNS ._SENT Interestingly_RB ,_, structure-activity_NN relationship_NN (_( SAR_NP )_) studies_NNS using_VBG different_JJ kinds_NNS of_IN natural_JJ and_CC synthetic_JJ model_NN peptides_NNS have_VBP revealed_VBN that_IN the_DT potencies_NNS and_CC spectra_NN of_IN the_DT antibacterial_NN activities_NNS of_IN amphipathic_JJ alpha-helical_JJ antimicrobial_JJ peptides_NNS can_MD be_VB influenced_VBN by_IN interrelated_VBN structural_JJ and_CC physicochemical_JJ parameters_NNS such_JJ as_IN charge_NN (_( cationicity_NN )_) ,_, hydrophobicity_NN ,_, and_CC amphipathicity_NN ._SENT Thus_RB ,_, it_PP could_MD be_VB anticipated_VBN that_IN by_IN changing_VBG these_DT parameters_NNS one_PP could_MD design_VB novel_JJ antimicrobial_JJ peptides_NNS with_IN increased_VBN potency_NN and_CC directed_JJ activity_NN which_WDT would_MD be_VB effective_JJ as_IN therapeutic_JJ agents_NNS for_IN bacterial_JJ infections_NNS and_CC their_PP$ related_JJ symptoms_NNS ._SENT FIG._NN 1_CD ._SENT |_SYM Helical_JJ wheel_NN projections_NNS for_IN LL-37_JJ and_CC its_PP$ 18-mer_JJ peptide_NN derivatives_NNS ._SENT Helical_JJ wheel_NN projections_NNS for_IN LL-37_JJ and_CC its_PP$ 18-mer_JJ peptide_NN derivatives_NNS ._SENT The_DT sequences_NNS of_IN alpha-helical_JJ peptides_NNS LL-37_JJ ,_, 18-mer_NP K15-V32_NP ,_, 18-mer_NP LL_NP ,_, and_CC 18-mer_NP LLKKK_NP are_VBP presented_VBN according_VBG to_TO the_DT Shiffer-Edmundson_NP wheel_NN projection_NN analyzed_VBD with_IN a_DT Genetyx-Mac_NP computer_NN system_NN (_( Software_NP Development_NP ,_, Tokyo_NP ,_, Japan_NP )_) ._SENT To_TO increase_VB hydrophobicity_NN ,_, E16_NP and_CC K25_NP in_IN 18-mer_NP K15-V32_NP were_VBD replaced_VBN by_IN L16_NP and_CC L25_NP in_IN 18-mer_NP LL_NP ,_, respectively_RB ._SENT Furthermore_RB ,_, to_TO increase_VB cationicity_NN ,_, Q22_NP ,_, D26_NP ,_, and_CC N30_NP in_IN 18-mer_NP LL_NP were_VBD replaced_VBN by_IN K22_NP ,_, K26_NP ,_, and_CC K30_NP in_IN 18-mer_NP LLKKK_NP ,_, respectively_RB ._SENT Positively_RB charged_VBN residues_NNS are_VBP circled_VBN ,_, whereas_IN negatively_RB charged_VBN residues_NNS are_VBP boxed_VBN ._SENT Hydrophobic_JJ residues_NNS are_VBP outlined_VBN ,_, while_IN neutral_JJ hydrophilic_JJ residues_NNS are_VBP not_RB ._SENT The_DT hydrophilic_JJ and_CC hydrophobic_JJ sectors_NNS are_VBP divided_VBN by_IN dashed_VBN lines_NNS ._SENT During_IN analysis_NN of_IN the_DT biological_JJ activities_NNS of_IN hCAP18/LL-37-derived_JJ antimicrobial_JJ peptides_NNS of_IN different_JJ sizes_NNS ,_, it_PP was_VBD found_VBN that_IN a_DT short_JJ fragment_NN peptide_NN (_( 18-mer_NP ;_: K15_NP to_TO V32_NP [_SYM K15-V32_NP ]_SYM )_) of_IN LL-37_JJ displayed_VBD an_DT amphipathic_JJ alpha-helical_JJ structure_NN and_CC possessed_JJ LPS-neutralizing_VBG activity_NN almost_RB equal_JJ to_TO that_DT of_IN the_DT parent_NN peptide_NN ,_, LL-37_JJ ;_: like_IN LL-37_JJ ,_, the_DT 18-mer_NP peptide_NN inhibited_VBD the_DT binding_NN of_IN LPS_NP to_TO CD14+_NP cells_NNS and_CC suppressed_VBN LPS-induced_JJ cytokine_NN production_NN by_IN these_DT cells_NNS ._SENT Thus_RB ,_, the_DT 18-mer_JJ peptide_NN may_MD be_VB a_DT good_JJ template_NN for_IN development_NN of_IN therapeutic_JJ agents_NNS that_WDT can_MD be_VB used_VBN for_IN prevention_NN of_IN gram-negative_JJ bacterial_JJ sepsis_NN and_CC endotoxin_NN shock_NN ._SENT In_IN this_DT study_NN ,_, therefore_RB ,_, to_TO develop_VB 18-mer_JJ peptides_NNS with_IN improved_VBN LPS-neutralizing_JJ activities_NNS ,_, we_PP modified_VBD the_DT hydrophobicity_NN and_CC cationicity_NN of_IN the_DT peptide_NN by_IN substitution_NN of_IN leucine_NN and_CC lysine_NN residues_NNS ,_, respectively_RB ,_, and_CC evaluated_VBD the_DT activities_NNS of_IN those_DT peptide_NN derivatives_NNS by_IN using_VBG the_DT CD14+_NP murine_JJ macrophage_NN cell_NN line_NN RAW_NP 264.7_CD and_CC the_DT murine_JJ endotoxin_NN shock_NN model_NN ._SENT Reagents_NNS ._SENT |_SYM Fluorescein_NP isothiocyanate_NN (FITC)-conjugated_JJ or_CC unconjugated_JJ LPS_NNS (_( from_IN Escherichia_NP coli_NNS O111:B4_NP )_) ,_, the_DT 3,3',5,5'-tetramethylbenzidine_JJ (_( TMB_NP )_) liquid_JJ substrate_NN system_NN ,_, and_CC d-galactosamine_NP were_VBD purchased_VBN from_IN Sigma_NP (_( St._NP Louis_NP ,_, Mo._NP )_) ._SENT In_IN some_DT experiments_NNS ,_, LPS_NP was_VBD biotinylated_JJ with_IN biotin-LC-hydrazide_NN ,_, based_VBN on_IN the_DT manufacturer_NN 's_POS protocol_NN (_( Pierce_NP ,_, Rockford_NP ,_, Ill._NP )_) ._SENT A_DT 37-mer_JJ peptide_NN of_IN hCAP18_NN (_( LL-37_NP ;_: L1LGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES37_NP )_) and_CC its_PP$ 18-mer_JJ derivatives_NNS (_( 18-mer_NP K15-V32_NP ,_, 18-mer_NP LL_NP ,_, and_CC 18-mer_NP LLKKK_NP )_) were_VBD synthesized_VBN by_IN the_DT solid-phase_NN method_NN on_IN a_DT peptide_NN synthesizer_NN (_( model_NN PSSM-8_NP ;_: Shimadzu_NP ,_, Kyoto_NP ,_, Japan_NP )_) by_IN fluorenylmethoxycarbonyl_NN (_( Fmoc_NP )_) chemistry_NN ._SENT The_DT peptides_NNS were_VBD eluted_VBN from_IN the_DT resin_NN and_CC purified_VBN to_TO homogeneity_NN by_IN reversed-phase_JJ high-performance_JJ liquid_JJ chromatography_NN on_IN a_DT Cosmosil_NP 5C18_JJ column_NN (_( Nacalai_NP Tesque_NP ,_, Kyoto_NP ,_, Japan_NP )_) by_IN use_NN of_IN a_DT 0_CD to_TO 70_CD %_NN acetonitrile_JJ gradient_NN in_IN 0.1_CD %_NN trifluoroacetic_JJ acid_NN ._SENT The_DT molecular_JJ masses_NNS of_IN the_DT peptides_NNS synthesized_VBN were_VBD confirmed_VBN on_IN a_DT mass_JJ spectrometer_NN (_( model_NN TSQ_NP 700_CD ;_: Thermo_NP Quest_NP Finnigan_NP ,_, Manchester_NP ,_, United_NP Kingdom_NP )_) ._SENT The_DT sequences_NNS of_IN the_DT peptides_NNS were_VBD as_RB follows_VBZ :_: 18-mer_NP K15-V32_NP ,_, K15EFKRIVQRIKDFLRNLV32_NP ;_: 18-mer_NP LL_NP ,_, K15LFKRIVQRILDFLRNLV32_NP ;_: 18-mer_NP LLKKK_NP ,_, K15LFKRIVKRILKFLRKLV32_NP (_( underlining_VBG indicates_VBZ amino_NN acid_NN substitutions_NNS introduced_VBN into_IN the_DT original_JJ 18-mer_JJ peptide_NN to_TO increase_VB hydrophobicity_NN or_CC cationicity_NN )_) ._SENT Tissue_NN culture_NN supplies_NNS were_VBD obtained_VBN from_IN Iwaki_NP Glass_NP (_( Tokyo_NP ,_, Japan_NP )_) ._SENT Antibodies_NNS ._SENT |_SYM As_IN anti-LPS-binding_NN protein_NN (_( LBP_NP )_) antibodies_NNS ,_, mouse_NN anti-human_NP LBP_NP monoclonal_NN antibody_NN (_( MAb_NP )_) 6G3_JJ (_( HyCult_NP Biotechnology_NP ,_, Uden_NP ,_, The_DT Netherlands_NPS )_) ,_, which_WDT can_MD cross-react_VB with_IN bovine_JJ LBP_NP ,_, and_CC rat_NN anti-mouse_NN LBP_NP MAb_NP clone_NN 39_CD (_( class_NN 2_CD )_) were_VBD used_VBN ._SENT These_DT anti-LBP_NP MAbs_NP can_MD recognize_VB both_DT free_JJ LBP_NP and_CC LBP-LPS_NP complexes_NNS ,_, and_CC they_PP inhibit_VBP the_DT transfer_NN of_IN LPS_NP to_TO CD14_NP ._SENT As_IN anti-CD14_JJ antibodies_NNS ,_, FITC-conjugated_JJ rat_NN anti-mouse_NN CD14_NP MAb_NP rmC5-3_NP (_( BD_NP PharMingen_NP ,_, San_NP Diego_NP ,_, Calif._NP )_) and_CC FITC-conjugated_JJ or_CC unconjugated_JJ rat_NN anti-mouse_NN CD14_NP MAb_NP 4C1_JJ were_VBD utilized_VBN ._SENT MAb_NN 4C1_JJ can_MD block_VB the_DT binding_NN of_IN LPS_NP to_TO CD14+_NP cells_NNS ,_, whereas_IN rmC5-3_NN has_VBZ little_JJ effect_NN on_IN LPS_NP binding_NN ._SENT Cells_NNS ._SENT |_SYM The_DT murine_JJ macrophage_NN cell_NN line_NN RAW_NP 264.7_CD was_VBD obtained_VBN from_IN the_DT American_NP Type_NP Culture_NP Collection_NP (_( Manassas_NP ,_, Va._NP )_) and_CC cultured_VBN in_IN RPMI_NP 1640_CD medium_NN (_( Nissui_NP Pharmaceutical_NP ,_, Tokyo_NP ,_, Japan_NP )_) supplemented_VBD with_IN 10_CD %_NN fetal_JJ bovine_JJ serum_NN (_( FBS_NP ;_: Sanko_NP Junyaku_NP ,_, Tokyo_NP ,_, Japan_NP )_) at_IN 37C_JJ under_IN 5_CD %_NN CO2_NN ._SENT Confluent_JJ RAW_NP 264.7_CD cells_NNS were_VBD detached_VBN by_IN washing_VBG with_IN 0.05_CD %_NN EDTA_NP in_IN phosphate-buffered_JJ saline_NN (_( PBS_NP )_) (_( 137_CD mM_NP NaCl_NP ,_, 2.7_CD mM_NP KCl_NP ,_, 8.1_CD mM_NP Na2HPO4_NP ,_, 1.5_CD mM_NP KH2PO4_NP [_SYM pH_NN 7.4_CD ]_SYM )_) and_CC suspended_VBN in_IN RPMI_NP 1640_CD containing_VBG 10_CD %_NN FBS_NP ._SENT Assay_NN for_IN binding_VBG of_IN FITC-conjugated_NP LPS_NP to_TO RAW_NP 264.7_CD cells_NNS ._SENT |_SYM RAW_NP 264.7_CD cells_NNS (_( 5_CD x_SYM 105/ml_JJ )_) were_VBD incubated_VBN with_IN FITC-conjugated_NP LPS_NP (_( 100_CD ng/ml_NNS )_) in_IN the_DT absence_NN or_CC presence_NN of_IN 18-mer_JJ peptides_NNS or_CC LL-37_JJ (_( 0.01_CD to_TO 10_CD mug/ml_NN )_) in_IN RPMI_NP 1640_CD containing_VBG 10_CD %_NN FBS_NP for_IN 15_CD min_NN at_IN 37C_JJ ._SENT After_IN cells_NNS were_VBD washed_VBN with_IN PBS_NP ,_, the_DT binding_NN of_IN FITC-conjugated_NP LPS_NP was_VBD analyzed_VBN by_IN flow_NN cytometry_NN (_( FACScan_NP ;_: Becton_NP Dickinson_NP ,_, Rutherford_NP ,_, N.J._NP )_) ,_, and_CC median_JJ fluorescence_NN intensity_NN was_VBD determined_VBN ._SENT Alternatively_RB ,_, RAW_NP 264.7_CD cells_NNS were_VBD incubated_VBN with_IN FITC-conjugated_NP LPS_NP in_IN the_DT presence_NN of_IN anti-human_NP LBP_NP MAb_NP 6G3_NP or_CC anti-mouse_NP CD14_NP MAb_NP 4C1_JJ at_IN 5_CD mug/ml_NN in_IN RPMI_NP 1640_CD containing_VBG 10_CD %_NN FBS_NP ,_, and_CC the_DT binding_NN of_IN FITC-conjugated_NP LPS_NP was_VBD analyzed_VBN as_IN described_VBN above_IN ._SENT In_IN some_DT experiments_NNS ,_, RAW_NP 264.7_CD cells_NNS were_VBD preincubated_VBN with_IN 18-mer_JJ peptides_NNS or_CC LL-37_JJ at_IN 1_CD mug/ml_NN in_IN RPMI_NP 1640_CD containing_VBG 10_CD %_NN FBS_NP for_IN 10_CD min_NN at_IN 37C_JJ ._SENT After_IN a_DT wash_NN ,_, cells_NNS were_VBD incubated_VBN with_IN FITC-conjugated_NP LPS_NP (_( 100_CD ng/ml_NNS )_) in_IN RPMI_NP 1640_CD containing_VBG 10_CD %_NN FBS_NP for_IN 15_CD min_NN at_IN 37C_JJ ,_, and_CC LPS_NP binding_NN was_VBD evaluated_VBN by_IN flow_NN cytometry_NN ._SENT In_IN separate_JJ experiments_NNS ,_, using_VBG RPMI_NP 1640_CD containing_VBG 10_CD %_NN mouse_NN serum_NN ,_, we_PP confirmed_VBD that_IN FITC-conjugated_NP LPS_NP could_MD bind_VB to_TO RAW_NP 264.7_CD cells_NNS ,_, and_CC the_DT binding_NN was_VBD completely_RB suppressed_VBN by_IN anti-mouse_NP LBP_NP MAb_NP clone_NN 39_CD and_CC anti-mouse_NP CD14_NP MAb_NP 4C1_JJ ._SENT Moreover_RB ,_, we_PP observed_VBD that_IN 18-mer_JJ peptides_NNS and_CC LL-37_JJ inhibited_VBD the_DT binding_NN of_IN FITC-conjugated_NP LPS_NP to_TO RAW_NP 264.7_CD cells_NNS and_CC LPS-induced_JJ tumor_NN necrosis_NN factor_NN alpha_NN (_( TNF-alpha_NP )_) expression_NN by_IN these_DT cells_NNS (_( see_VB below_IN )_) in_IN the_DT medium_NN containing_VBG 10_CD %_NN mouse_NN serum_NN ,_, as_RB in_IN the_DT medium_NN containing_VBG 10_CD %_NN FBS_NP (_( data_NN not_RB shown_VBN )_) ._SENT These_DT findings_NNS suggest_VBP the_DT possibility_NN that_IN the_DT peptides_NNS could_MD function_VB in_IN mice_NNS ._SENT Evaluation_NN of_IN TNF-alpha_NP expression_NN ._SENT |_SYM RAW_NP 264.7_CD cells_NNS (_( 106/well_NP in_IN a_DT 24-well_JJ microplate_NN )_) were_VBD incubated_VBN with_IN LPS_NP (_( 100_CD ng/ml_NNS )_) in_IN the_DT absence_NN or_CC presence_NN of_IN 18-mer_JJ peptides_NNS or_CC LL-37_JJ at_IN 1_CD mug/ml_NN in_IN 500_CD mul_NN of_IN RPMI_NP 1640_CD containing_VBG 10_CD %_NN FBS_NP for_IN 4_CD h_NN at_IN 37C_JJ ._SENT After_IN incubation_NN ,_, cells_NNS were_VBD detached_VBN by_IN a_DT wash_NN with_IN 0.05_CD %_NN EDTA-PBS_NNS ,_, and_CC expression_NN of_IN TNF-alpha_NP mRNA_NN and_CC protein_NN was_VBD analyzed_VBN by_IN Northern_NP and_CC Western_JJ blotting_VBG ,_, respectively_RB ._SENT In_IN brief_JJ ,_, total_JJ cellular_JJ RNA_NP (_( 2.5_CD mug_NN )_) was_VBD separated_VBN by_IN electrophoresis_NN on_IN a_DT 1_CD %_NN agarose-formaldehyde_NN gel_NN ,_, and_CC Northern_JJ blot_NN hybridization_NN was_VBD performed_VBN by_IN using_VBG cDNA_NN probes_NNS labeled_VBN with_IN a_DT digoxigenin-High_JJ Prime_NP DNA_NP labeling_VBG kit_NN (_( Roche_NP Diagnostics_NP ,_, Mannheim_NP ,_, Germany_NP )_) ;_: probes_NNS used_VBN were_VBD the_DT 0.39-kb_NN mouse_NN TNF-alpha_NP cDNA_NN (_( encompassing_VBG nucleotides_NNS 427_CD to_TO 819_CD )_) and_CC the_DT 2.1-kb_JJ beta-actin_NN cDNA_NN (_( pHFbetaA-1_JJ )_) ._SENT In_IN Western_JJ blot_NN analysis_NN ,_, cell_NN sonicates_NNS in_IN PBS_NP containing_VBG 1_CD mM_NP diisopropyl_NN fluorophosphate_NN (_( 3_CD x_SYM 105_CD cells_NNS for_IN TNF-alpha_NP and_CC 3_CD x_SYM 104_CD cells_NNS for_IN beta-actin_NN )_) were_VBD subjected_VBN to_TO sodium_NN dodecyl_NN sulfate-polyacrylamide_NN gel_NN electrophoresis_NN on_IN a_DT 7.5_CD to_TO 20_CD %_NN linear_JJ gradient_NN of_IN polyacrylamide_NN under_IN reducing_VBG conditions_NNS ._SENT Resolved_JJ proteins_NNS were_VBD electrotransferred_VBN to_TO an_DT Immobilon-P_NP membrane_NN (_( Millipore_NP ,_, Bedford_NP ,_, Mass._NP )_) ,_, and_CC blots_NNS were_VBD probed_VBN with_IN a_DT rabbit_NN anti-mouse_NN TNF-alpha_NP antibody_NN (_( Ab_NP )_) (_( Genzyme_NP Diagnostics_NP ,_, Cambridge_NP ,_, Mass._NP )_) or_CC an_DT anti-beta-actin_NP MAb_NP (_( Sigma_NP )_) ._SENT Blots_NNS were_VBD further_RBR probed_VBN with_IN horseradish_NN peroxidase_NN (HRP)-conjugated_JJ goat_NN anti-rabbit_NN immunoglobulin_NN G_NP (_( IgG_NP )_) (_( Organon_NP Teknika_NP ,_, Durham_NP ,_, N.C._NP )_) or_CC goat_NN anti-mouse_NN IgG/IgM_NP (_( Chemicon_NP International_NP ,_, Temecula_NP ,_, Calif._NP )_) ,_, and_CC proteins_NNS were_VBD finally_RB detected_VBN with_IN SuperSignal_NP West_NP Pico_NP chemiluminescent_JJ substrate_NN (_( Pierce_NP )_) ._SENT In_IN some_DT experiments_NNS ,_, RAW_NP 264.7_CD cells_NNS were_VBD incubated_VBN with_IN LPS_NP in_IN the_DT medium_NN containing_VBG 10_CD %_NN mouse_NN serum_NN ,_, and_CC the_DT effects_NNS of_IN 18-mer_JJ peptides_NNS and_CC LL-37_JJ on_IN LPS-induced_NP TNF-alpha_NP expression_NN were_VBD investigated_VBN as_IN described_VBN above_IN ._SENT Measurement_NN of_IN LPS-binding_NP activities_NNS of_IN 18-mer_JJ peptides_NNS ._SENT |_SYM Ninety-six-well_NP microtiter_NN plates_NNS (_( Immulon_NP 2H_NP ;_: Dynex_NP Technologies_NPS ,_, Ashford_NP ,_, United_NP Kingdom_NP )_) were_VBD coated_VBN with_IN LPS_NP (_( 100_CD ng/well_NNS )_) as_RB described_VBD previously_RB ._SENT Excess_JJ binding_JJ sites_NNS were_VBD blocked_VBN with_IN 100_CD mul_NN of_IN PBS_NP containing_VBG 1_CD %_NN bovine_JJ serum_NN albumin_NN (BSA)/well_NN ,_, and_CC 18-mer_JJ peptides_NNS and_CC LL-37_JJ (_( 0.02_CD to_TO 0.5_CD mug/well_NN )_) were_VBD incubated_VBN in_IN the_DT plates_NNS for_IN 1_CD h_NN at_IN 37C_JJ in_IN 50_CD mul_NN of_IN RPMI_NP 1640_CD without_IN phenol_NN red_NN (_( Life_NP Technologies_NP ,_, Grand_NP Island_NP ,_, N.Y_NP )_) ._SENT Alternatively_RB ,_, 18-mer_JJ peptides_NNS and_CC LL-37_JJ (_( 0.1_CD mug/well_NN )_) were_VBD incubated_VBN in_IN the_DT presence_NN of_IN LPS_NP (_( 0.05_CD to_TO 2.5_CD mug/well_NN )_) in_IN 50_CD mul_NN of_IN RPMI_NP 1640_CD ._SENT After_IN a_DT wash_NN ,_, an_DT affinity-purified_JJ rabbit_NN anti-CAP18_NP Ab_NP (_( 50_CD mul/well_NN ;_: 2_CD mug/ml_NN in_IN PBS_NP containing_VBG 0.1_CD %_NN BSA_NP )_) was_VBD added_VBN and_CC incubated_VBN for_IN 1_CD h_NN at_IN 37C_JJ in_IN the_DT plates_NNS ._SENT The_DT Ab_NP solution_NN was_VBD then_RB rinsed_VBN out_RP ,_, and_CC HRP-conjugated_JJ goat_NN anti-rabbit_NN IgG_NP (_( 50_CD mul/well_NN ;_: diluted_JJ 2,000-fold_NN in_IN PBS_NP containing_VBG 0.1_CD %_NN BSA_NP )_) was_VBD incubated_VBN for_IN 1_CD h_NN at_IN room_NN temperature_NN ._SENT Finally_RB ,_, a_DT TMB_NP liquid_JJ substrate_NN (_( 100_CD mul/well_NN )_) was_VBD incubated_VBN for_IN 5_CD to_TO 15_CD min_NN ._SENT The_DT reaction_NN was_VBD stopped_VBN by_IN addition_NN of_IN 100_CD mul_NN of_IN 0.18_CD M_NP sulfuric_JJ acid/well_NN ,_, and_CC absorbances_NNS at_IN 450_CD and_CC 560_CD nm_NN were_VBD quantitated_VBN in_IN a_DT microtiter_NN plate_NN reader_NN ._SENT An_DT anti-CAP18_JJ serum_NN was_VBD raised_VBN in_IN rabbits_NNS by_IN use_NN of_IN the_DT LL-37_JJ peptide_NN covalently_RB coupled_VBN to_TO keyhole_NN limpet_NN hemocyanin_NN ,_, and_CC the_DT Ab_NP was_VBD purified_VBN by_IN affinity_NN chromatography_NN using_VBG LL-37_JJ peptide-conjugated_JJ ,_, epoxy-activated_JJ Sepharose_NP (_( Amersham_NP Pharmacia_NP Biotech_NP )_) ._SENT In_IN preliminary_JJ experiments_NNS ,_, we_PP confirmed_VBD that_IN the_DT anti-CAP18_NP Ab_NP could_MD recognize_VB not_RB only_RB LL-37_JJ but_CC also_RB 18-mer_NP K15-V32_NP ,_, 18-mer_NP LL_NP ,_, and_CC 18-mer_NP LLKKK_NP (_( data_NN not_RB shown_VBN )_) ._SENT Assay_NN for_IN interaction_NN of_IN LPS_NP with_IN LBP_NP ._SENT |_SYM LPS_NP (_( 100_CD ng/well_NNS )_) was_VBD used_VBN to_TO coat_VB the_DT 96-well-microtiter_NN plates_NNS as_RB described_VBD above_IN ._SENT After_IN blocking_VBG ,_, RPMI_NP 1640_CD containing_VBG 0.1_CD ,_, 1_CD ,_, or_CC 10_CD %_NN FBS_NP (_( 50_CD mul/well_NN )_) was_VBD added_VBN and_CC incubated_VBN for_IN 1_CD h_NN at_IN 37C_JJ ._SENT Plates_NNS were_VBD then_RB washed_VBN ,_, and_CC 50_CD mul_NN of_IN anti-LBP_NP MAb_NP 6G3_NP (_( 25_CD nM_NN in_IN PBS_NP containing_VBG 0.1_CD %_NN BSA)/well_NP was_VBD incubated_VBN in_IN the_DT plates_NNS for_IN 1_CD h_NN at_IN 37C_JJ ._SENT The_DT MAb_NP solution_NN was_VBD rinsed_VBN out_RP ,_, and_CC 50_CD mul_NN of_IN HRP-conjugated_JJ rabbit_NN anti-mouse_NN IgG_NP (_( Dako_NP ,_, Glostrup_NP ,_, Denmark_NP ;_: diluted_JJ 1,000-fold_NN in_IN PBS_NP containing_VBG 0.1_CD %_NN BSA)/well_NP was_VBD incubated_VBN for_IN 1_CD h_NN at_IN room_NN temperature_NN ._SENT Finally_RB ,_, binding_VBG of_IN LBP_NP to_TO the_DT immobilized_VBN LPS_NP was_VBD detected_VBN by_IN incubation_NN with_IN TMB_NP liquid_JJ substrate_NN (_( 100_CD mul/well_NN )_) ._SENT Alternatively_RB ,_, the_DT LPS_NP microtiter_NN plates_NNS were_VBD preincubated_VBN with_IN 18-mer_JJ peptides_NNS or_CC LL-37_JJ (_( 0.025_CD to_TO 0.2_CD mug/well_NN )_) in_IN 50_CD mul_NN of_IN RPMI_NP 1640/well_NP for_IN 1_CD h_NN at_IN 37C_JJ ._SENT After_IN a_DT wash_NN ,_, RPMI_NP 1640_CD containing_VBG 10_CD %_NN FBS_NP (_( 50_CD mul/well_NN )_) was_VBD added_VBN ,_, and_CC binding_VBG of_IN LBP_NP was_VBD determined_VBN as_IN described_VBN above_IN ._SENT Assay_NN for_IN binding_VBG of_IN LBP_NP to_TO 18-mer_JJ peptides_NNS ._SENT |_SYM Microtiter_NP plates_NNS were_VBD coated_VBN with_IN 18-mer_JJ peptides_NNS or_CC LL-37_JJ (_( 2.5_CD mug/well_NN )_) by_IN incubating_VBG 50_CD mul_NN of_IN 50-mug/ml_JJ peptides_NNS in_IN PBS/well_NP overnight_JJ at_IN room_NN temperature_NN ._SENT After_IN blocking_VBG ,_, RPMI_NP 1640_CD containing_VBG 10_CD %_NN FBS_NP (_( 50_CD mul/well_NN )_) was_VBD added_VBN and_CC incubated_VBN for_IN 1_CD h_NN at_IN 37C_JJ ._SENT Plates_NNS were_VBD then_RB washed_VBN ,_, and_CC 50_CD mul_NN of_IN anti-LBP_NP MAb_NP 6G3_NP (_( 25_CD nM_NN in_IN PBS_NP containing_VBG 0.1_CD %_NN BSA)/well_NP was_VBD incubated_VBN in_IN the_DT plates_NNS for_IN 1_CD h_NN at_IN 37C_JJ ._SENT The_DT MAb_NP solution_NN was_VBD rinsed_VBN out_RP and_CC replaced_VBD with_IN 50_CD mul_NN of_IN HRP-conjugated_JJ rabbit_NN anti-mouse_NN IgG_NP (_( diluted_JJ 1,000-fold_NN in_IN PBS_NP containing_VBG 0.1_CD %_NN BSA)/well_NP for_IN 1_CD h_NN at_IN room_NN temperature_NN ._SENT Finally_RB ,_, binding_VBG of_IN LBP_NP to_TO the_DT immobilized_VBN peptides_NNS was_VBD detected_VBN by_IN TMB_NP reaction_NN ._SENT As_IN a_DT positive_JJ control_NN ,_, biotinylated_JJ LPS_NP (_( 100_CD ng/well_NNS )_) was_VBD added_VBN to_TO plates_NNS coated_VBN with_IN 18-mer_JJ peptides_NNS or_CC LL-37_JJ ,_, and_CC the_DT plates_NNS were_VBD incubated_VBN for_IN 1_CD h_NN at_IN 37C_JJ in_IN 50_CD mul_NN of_IN RPMI_NP 1640/well_NP ._SENT The_DT LPS_NP solution_NN was_VBD then_RB rinsed_VBN out_RP ,_, and_CC 50_CD mul_NN of_IN HRP-conjugated_NP streptavidin_NP (_( Dako_NP ;_: diluted_JJ 5,000-fold_NN in_IN PBS_NP containing_VBG 0.1_CD %_NN BSA)/well_NP was_VBD incubated_VBN for_IN 1_CD h_NN at_IN 37C_JJ ._SENT Binding_VBG of_IN biotinylated_JJ LPS_NP to_TO the_DT peptides_NNS that_WDT had_VBD been_VBN used_VBN to_TO coat_VB the_DT wells_NNS was_VBD finally_RB detected_VBN by_IN TMB_NP reaction_NN ._SENT Flow_NN cytometric_JJ assay_NN for_IN expression_NN of_IN CD14_NP and_CC binding_VBG of_IN 18-mer_JJ peptides_NNS to_TO CD14_NP ._SENT |_SYM To_TO analyze_VB the_DT effects_NNS of_IN 18-mer_JJ peptides_NNS and_CC LL-37_JJ on_IN CD14_NP expression_NN ,_, RAW_NP 264.7_CD cells_NNS (_( 5_CD x_SYM 105/ml_JJ )_) were_VBD incubated_VBN without_IN or_CC with_IN the_DT peptides_NNS (_( 1_CD mug/ml_NN )_) or_CC LPS_NP (_( 100_CD ng/ml_NNS )_) in_IN RPMI_NP 1640_CD containing_VBG 10_CD %_NN FBS_NP for_IN 15_CD min_NN at_IN 37C_NP and_CC were_VBD further_RBR incubated_VBN with_IN FITC-conjugated_JJ rat_NN anti-mouse_NN CD14_NP MAb_NP rmC5-3_NN (_( 2.5_CD mug/ml_NN )_) ,_, or_CC with_IN FITC-conjugated_JJ rabbit_NN anti-mouse_NN IgG_NP (_( Dako_NP )_) as_IN a_DT negative_JJ control_NN ,_, for_IN 15_CD min_NN at_IN 37C_JJ ._SENT After_IN a_DT wash_NN ,_, the_DT binding_NN of_IN the_DT anti-CD14_NP MAb_NP was_VBD measured_VBN by_IN flow_NN cytometry_NN ._SENT Furthermore_RB ,_, the_DT binding_NN of_IN 18-mer_JJ peptides_NNS and_CC LL-37_JJ to_TO CD14_NP was_VBD examined_VBN by_IN using_VBG the_DT neutralizing_VBG anti-mouse_NN CD14_NP MAb_NP 4C1_JJ ,_, which_WDT recognizes_VBZ the_DT murine_JJ CD14_NP epitope_NN located_VBN near_IN the_DT LPS-binding_NP site_NN ._SENT RAW_JJ 264.7_CD cells_NNS (_( 5_CD x_SYM 105/ml_JJ )_) were_VBD preincubated_VBN without_IN or_CC with_IN the_DT peptides_NNS (_( 1_CD mug/ml_NN )_) ,_, or_CC with_IN LPS_NP (_( 100_CD ng/ml_NNS )_) as_IN a_DT positive_JJ control_NN ,_, for_IN 15_CD min_NN at_IN 37C_JJ in_IN RPMI_NP 1640_CD containing_VBG 10_CD %_NN FBS_NP ._SENT Cells_NNS were_VBD then_RB added_VBN with_IN 50_CD ng_NNS of_IN FITC-conjugated_NP anti-CD14_NP MAb_NP 4C1/ml_NP ,_, or_CC with_IN 50_CD ng_NNS of_IN FITC-conjugated_JJ rabbit_NN anti-mouse_NN IgG/ml_NP as_IN a_DT negative_JJ control_NN ,_, and_CC were_VBD further_RBR incubated_VBN for_IN 15_CD min_NN at_IN 37C_JJ ._SENT After_IN a_DT wash_NN ,_, the_DT binding_NN of_IN FITC-conjugated_NP anti-CD14_NP MAb_NP 4C1_JJ was_VBD analyzed_VBN by_IN flow_NN cytometry_NN ._SENT Evaluation_NN of_IN effects_NNS of_IN 18-mer_JJ peptides_NNS on_IN the_DT murine_JJ endotoxin_NN shock_NN model_NN ._SENT |_SYM To_TO determine_VB the_DT protective_JJ activities_NNS of_IN 18-mer_JJ peptides_NNS against_IN lethal_JJ LPS_NP activity_NN ,_, we_PP utilized_VBD d-galactosamine-sensitized_JJ mice_NNS ,_, which_WDT are_VBP highly_RB susceptible_JJ to_TO LPS_NP ._SENT d-Galactosamine_NP (_( 18_CD mg/0.3_NN ml_NN of_IN saline_NN )_) ,_, LPS_NP (_( 200_CD ng/0.2_JJ ml_NN of_IN saline_NN )_) ,_, and_CC 18-mer_JJ peptides_NNS or_CC LL-37_JJ (_( 1_CD mug/0.2_NN ml_NN of_IN saline_NN )_) were_VBD sequentially_RB injected_VBN intraperitoneally_RB (_( i.p._JJ )_) into_IN male_JJ C57BL/6_NP mice_NNS aged_VBN 10_CD weeks_NNS (_( Charles_NP River_NP Japan_NP ,_, Kanagawa_NP ,_, Japan_NP )_) ,_, and_CC deaths_NNS were_VBD recorded_VBN every_DT 24_CD h_NN until_IN day_NN 6_CD after_IN injection_NN ._SENT Furthermore_RB ,_, 75_CD min_NN after_IN LPS_NP challenge_NN ,_, mice_NNS were_VBD sacrificed_VBN by_IN drawing_VBG blood_NN from_IN the_DT heart_NN ,_, and_CC serum_NN samples_NNS were_VBD prepared_VBN ._SENT Serum_NP TNF-alpha_NP levels_NNS were_VBD determined_VBN by_IN using_VBG a_DT commercially_RB available_JJ mouse_NN TNF-alpha_NP enzyme-linked_JJ immunosorbent_JJ assay_NN kit_NN (_( Endogen_NP ,_, Woburn_NP ,_, Mass._NP )_) that_WDT can_MD detect_VB <9_JJ pg_NN of_IN TNF-alpha/ml_NP ._SENT In_IN some_DT experiments_NNS ,_, 75_CD min_NN after_IN challenge_NN with_IN d-galactosamine_NP (_( 18_CD mg_NN )_) ,_, FITC-conjugated_NP LPS_NP (_( 200_CD ng_NNS )_) ,_, and_CC 18-mer_JJ peptides_NNS or_CC LL-37_JJ (_( 1_CD mug_NN )_) ,_, peritoneal_JJ fluids_NNS were_VBD harvested_VBN by_IN washing_VBG the_DT peritoneal_JJ cavities_NNS with_IN PBS_NP ,_, and_CC peritoneal_JJ macrophages_NNS were_VBD recovered_VBN ._SENT Binding_VBG of_IN FITC-conjugated_NP LPS_NP to_TO peritoneal_JJ macrophages_NNS was_VBD analyzed_VBN by_IN flow_NN cytometry_NN ,_, and_CC expression_NN of_IN TNF-alpha_NP in_IN peritoneal_JJ macrophages_NNS was_VBD investigated_VBN by_IN Northern_NP and_CC Western_JJ blotting_VBG ,_, as_RB described_VBN above_IN ._SENT The_DT experiments_NNS were_VBD carried_VBN out_RP in_IN accordance_NN with_IN institutional_JJ guidelines_NNS ,_, and_CC mice_NNS received_VBD proper_JJ care_NN and_CC maintenance_NN ._SENT Statistical_JJ analysis_NN ._SENT |_SYM Data_NP are_VBP shown_VBN as_IN means_NN +-_NN standard_JJ deviations_NNS (_( SD_NP )_) ._SENT Statistical_JJ significance_NN was_VBD determined_VBN by_IN one-way_JJ analysis_NN of_IN variance_NN with_IN a_DT multiple-comparison_NN test_NN (_( StatView_NP ;_: Abacus_NP Concepts_NP ,_, Berkeley_NP ,_, Calif._NP )_) unless_IN otherwise_RB noted_VBN ._SENT Survival_NN in_IN mice_NNS after_IN LPS_NP administration_NN was_VBD assessed_VBN by_IN a_DT chi2_JJ test_NN (_( StatView_NP )_) ._SENT A_DT P_NN value_NN of_IN <0.05_NN was_VBD considered_VBN to_TO be_VB significant_JJ ._SENT Effects_NNS of_IN 18-mer_JJ peptides_NNS on_IN binding_VBG of_IN FITC-conjugated_NP LPS_NP to_TO RAW_NP 264.7_CD cells_NNS ._SENT |_SYM We_PP first_RB examined_VBD the_DT effects_NNS of_IN 18-mer_JJ peptides_NNS on_IN the_DT binding_NN of_IN FITC-conjugated_NP LPS_NP to_TO CD14+_NP cells_NNS by_IN flow_NN cytometry_NN using_VBG the_DT murine_JJ macrophage_NN cell_NN line_NN RAW_NP 264.7_CD ._SENT When_WRB FITC-conjugated_NP LPS_NP was_VBD incubated_VBN with_IN RAW_NP 264.7_CD cells_NNS in_IN the_DT presence_NN of_IN serum_NN ,_, it_PP bound_VBD to_TO the_DT cells_NNS ._SENT However_RB ,_, when_WRB FITC-conjugated_NP LPS_NP was_VBD incubated_VBN with_IN RAW_NP 264.7_CD cells_NNS in_IN the_DT presence_NN of_IN a_DT neutralizing_VBG anti-LBP_NP MAb_NP or_CC anti-CD14_NP MAb_NP ,_, LPS_NP binding_NN was_VBD completely_RB inhibited_VBN to_TO the_DT background_NN level_NN (_( the_DT level_NN without_IN FITC-conjugated_NP LPS_NP )_) ,_, indicating_VBG that_IN LPS_NP binds_VBZ to_TO the_DT cellular_JJ CD14_NP molecule_NN via_IN the_DT action_NN of_IN LBP_NP in_IN serum_NN ._SENT Interestingly_RB ,_, 18-mer_JJ peptides_NNS as_IN well_RB as_RB LL-37_JJ (_( 1_CD mug/ml_NN each_DT )_) markedly_RB suppressed_VBD the_DT binding_NN of_IN FITC-conjugated_NP LPS_NP to_TO RAW_NP 264.7_CD cells_NNS ._SENT Their_PP$ effects_NNS were_VBD dose_NN dependent_JJ ,_, and_CC 18-mer_NP LLKKK_NP (_( 50_CD %_NN inhibitory_JJ concentration_NN [_SYM IC50_NP ]_SYM ,_, 0.09_CD mug/ml_NN ,_, or_CC 0.043_CD muM_NN )_) was_VBD the_DT most_RBS potent_JJ of_IN the_DT peptides_NNS tested_VBN at_IN inhibiting_VBG the_DT binding_NN of_IN FITC-conjugated_NP LPS_NP to_TO RAW_NP 264.7_CD cells_NNS (_( for_IN 18-mer_NP LL_NP ,_, the_DT IC50_NP was_VBD 0.23_CD mug/ml_NN ,_, or_CC 0.102_CD muM_NN ;_: for_IN 18-mer_NP K15-V32_NP ,_, the_DT IC50_NP was_VBD 0.31_CD mug/ml_NN ,_, or_CC 0.136_CD muM_NN ;_: for_IN LL-37_JJ ,_, the_DT IC50_NP was_VBD 0.31_CD mug/ml_NN ,_, or_CC 0.070_CD muM_NN )_) ._SENT Furthermore_RB ,_, the_DT effects_NNS of_IN 18-mer_JJ peptides_NNS on_IN TNF-alpha_NP expression_NN were_VBD examined_VBN by_IN Northern_NP and_CC Western_JJ blot_NN analyses_NNS ._SENT The_DT 18-mer_JJ peptides_NNS and_CC LL-37_JJ (_( 1_CD mug/ml_NN )_) apparently_RB suppressed_VBD LPS-induced_NP TNF-alpha_NP expression_NN by_IN RAW_NP 264.7_CD cells_NNS at_IN both_CC the_DT mRNA_NN and_CC protein_NN levels_NNS ,_, and_CC the_DT effect_NN of_IN 18-mer_NP LLKKK_NP was_VBD the_DT most_RBS prominent_JJ ._SENT Eighteen-mer_NP LLKKK_NP also_RB exerted_VBD the_DT most_RBS suppressive_JJ action_NN on_IN LPS-induced_NP TNF-alpha_NP expression_NN by_IN RAW_NP 264.7_CD cells_NNS at_IN 0.1_CD mug/ml_NN among_IN the_DT peptide_NN derivatives_NNS investigated_VBN (_( data_NNS not_RB shown_VBN )_) ._SENT LPS-binding_NN activities_NNS of_IN 18-mer_JJ peptides_NNS and_CC their_PP$ effects_NNS on_IN the_DT binding_NN of_IN LPS_NP to_TO LBP_NP ._SENT |_SYM In_IN order_NN to_TO clarify_VB the_DT mechanisms_NNS by_IN which_WDT 18-mer_NP peptides_NNS inhibit_VBP the_DT binding_NN of_IN LPS_NP to_TO CD14+_NP cells_NNS ,_, we_PP investigated_VBD the_DT LPS-binding_NP activities_NNS of_IN these_DT peptides_NNS by_IN using_VBG LPS-coated_JJ microtiter_NN plates_NNS ._SENT The_DT 18-mer_JJ peptides_NNS and_CC LL-37_JJ bound_NN to_TO the_DT LPS-coated_JJ plates_NNS in_IN a_DT dose-dependent_JJ fashion_NN ,_, and_CC the_DT binding_NN was_VBD dose-dependently_RB inhibited_VBN by_IN addition_NN of_IN LPS_NP to_TO the_DT plates_NNS ._SENT Notably_RB ,_, the_DT binding_NN of_IN 18-mer_NP LLKKK_NP was_VBD more_JJR potently_RB inhibited_VBN by_IN LPS_NP addition_NN (_( IC50_NP ,_, 0.08_CD mug_NN of_IN LPS/well_NP )_) than_IN that_DT of_IN the_DT other_JJ peptides_NNS ;_: IC50s_NP of_IN LPS_NP ,_, in_IN micrograms_NNS per_IN well_RB ,_, were_VBD 0.16_CD for18-mer_NN LL_NP ,_, 0.25_CD for_IN 18-mer_NP K15-V32_NP ,_, and_CC 0.34_CD for_IN LL-37_JJ ._SENT Using_VBG the_DT LPS-coated_JJ plates_NNS ,_, we_PP next_RB examined_VBD the_DT effects_NNS of_IN 18-mer_JJ peptides_NNS on_IN the_DT interaction_NN between_IN LPS_NP and_CC LBP_NP ,_, which_WDT catalyzes_VBZ the_DT transfer_NN of_IN LPS_NP to_TO CD14_NP ._SENT When_WRB LPS-coated_NP plates_NNS were_VBD incubated_VBN with_IN FBS_NP ,_, the_DT LBP_NP in_IN the_DT serum_NN bound_VBN to_TO the_DT LPS-coated_JJ plates_NNS proportionately_RB to_TO the_DT concentrations_NNS of_IN serum_NN used_VBN ._SENT When_WRB the_DT LPS-coated_JJ plates_NNS were_VBD pretreated_VBN with_IN the_DT peptide_NN derivatives_NNS ,_, binding_VBG of_IN LBP_NP to_TO the_DT LPS-coated_JJ plates_NNS was_VBD inhibited_VBN in_IN a_DT dose-dependent_JJ manner_NN by_IN addition_NN of_IN 18-mer_JJ peptides_NNS or_CC LL-37_JJ to_TO the_DT plates_NNS ._SENT Importantly_RB ,_, 18-mer_NP LLKKK_NP (_( IC50_NP ,_, 0.018_CD mug/well_NN ,_, or_CC 7.9_CD pmol/well_NN )_) was_VBD the_DT most_RBS potent_JJ of_IN the_DT 18-mer_JJ peptides_NNS at_IN inhibiting_VBG LPS-LBP_NP binding_NN ;_: other_JJ IC50s_NNS were_VBD 0.024_CD mug/well_NN ,_, or_CC 10.9_CD pmol/well_NN ,_, for_IN 18-mer_NP LL_NP ;_: 0.035_CD mug/well_NN ,_, or_CC 15.2_CD pmol/well_NN ,_, for_IN 18-mer_NP K15-V32_NP ;_: and_CC 0.025_CD mug/well_NN ,_, or_CC 5.4_CD pmol/well_NN ,_, for_IN LL-37_JJ ._SENT Furthermore_RB ,_, we_PP evaluated_VBD the_DT interaction_NN of_IN LBP_NP with_IN the_DT peptides_NNS by_IN using_VBG 18-mer_JJ peptide-_NN or_CC LL-37-coated_JJ microtiter_NN plates_NNS ._SENT Apparently_RB ,_, substantial_JJ amounts_NNS of_IN biotinylated_JJ LPS_NP ,_, a_DT positive_JJ control_NN ,_, bound_VBN to_TO the_DT 18-mer_JJ peptide-_NN or_CC LL-37-coated_JJ plates_NNS ._SENT In_IN contrast_NN ,_, LBP_NP hardly_RB bound_VBN to_TO the_DT plates_NNS (_( data_NNS not_RB shown_VBN )_) ._SENT The_DT observations_NNS described_VBD above_RB indicate_VB that_IN the_DT 18-mer_NP K15-V32_NP ,_, 18-mer_NP LL_NP ,_, and_CC 18-mer_NP LLKKK_NP peptides_NNS have_VBP potential_JJ to_TO bind_VB to_TO LPS_NP ,_, but_CC not_RB LBP_NP ,_, thereby_RB inhibiting_VBG the_DT interaction_NN of_IN LPS_NP with_IN LBP_NP ._SENT Moreover_RB ,_, 18-mer_NP LLKKK_NP appears_VBZ to_TO be_VB the_DT most_RBS potent_JJ at_IN binding_VBG to_TO LPS_NP and_CC inhibiting_VBG LPS-LBP_NP interaction_NN ._SENT Effects_NNS of_IN 18-mer_JJ peptides_NNS on_IN CD14_NP expression_NN and_CC binding_VBG of_IN 18-mer_JJ peptides_NNS to_TO CD14+_NP cells_NNS ._SENT |_SYM It_PP is_VBZ possible_JJ that_IN antimicrobial_JJ peptides_NNS may_MD alter_VB CD14_NP expression_NN ,_, thereby_RB affecting_VBG the_DT binding_NN of_IN LPS_NP to_TO CD14+_NP cells_NNS ._SENT To_TO check_VB this_DT ,_, we_PP investigated_VBD the_DT expression_NN of_IN CD14_NP after_IN treatment_NN of_IN RAW_NP 264.7_CD cells_NNS with_IN 18-mer_JJ peptides_NNS by_IN flow_NN cytometry_NN using_VBG FITC-conjugated_NP anti-mouse_NP CD14_NP MAb_NP rmC5-3_NN ._SENT Neither_CC 18-mer_JJ peptides_NNS LL-37_JJ (_( 1_CD mug/ml_NN each_DT )_) ,_, nor_CC LPS_NP (_( 100_CD ng/ml_NNS )_) altered_VBN CD14_NP expression_NN on_IN RAW_NP 264.7_CD cells_NNS ._SENT Likewise_RB ,_, it_PP is_VBZ conceivable_JJ that_IN antimicrobial_JJ peptides_NNS bind_NN to_TO the_DT CD14_NP molecule_NN on_IN the_DT cells_NNS and_CC influence_VB the_DT binding_NN of_IN LPS_NP to_TO CD14+_NP cells_NNS without_IN affecting_VBG CD14_NP expression_NN ._SENT To_TO confirm_VB this_DT ,_, RAW_NP 264.7_CD cells_NNS were_VBD preincubated_VBN with_IN 18-mer_JJ peptides_NNS ,_, and_CC after_IN a_DT wash_NN ,_, the_DT binding_NN of_IN FITC-conjugated_NP LPS_NP was_VBD analyzed_VBN by_IN flow_NN cytometry_NN ._SENT Interestingly_RB ,_, preincubation_NN with_IN 18-mer_NP LLKKK_NP or_CC 18-mer_NP LL_NP (_( 1_CD mug/ml_NN )_) inhibited_VBD the_DT binding_NN of_IN FITC-conjugated_NP LPS_NP to_TO RAW_NP 264.7_CD cells_NNS by_IN 33.9_CD %_NN +-_NN 0.1_CD %_NN or_CC 22.5_CD %_NN +-_NN 2.6_CD %_NN ,_, respectively_RB (_( n_NN =_SYM 3_CD ;_: P_NN <_SYM 0.001_CD for_IN comparison_NN with_IN binding_VBG of_IN FITC-conjugated_NP LPS_NP in_IN the_DT absence_NN of_IN peptides_NNS )_) ,_, while_IN preincubation_NN with_IN 18-mer_NP K15-V32_NP or_CC LL-37_NP inhibited_VBD LPS_NP binding_VBG by_IN only_RB 5_CD to_TO 7_CD %_NN ._SENT To_TO further_RBR clarify_VB the_DT binding_NN of_IN peptides_NNS to_TO the_DT CD14_NP molecule_NN ,_, we_PP utilized_VBD anti-CD14_NP MAb_NP 4C1_JJ ,_, which_WDT can_MD recognize_VB the_DT murine_JJ CD14_NP epitope_NN and_CC inhibit_VB the_DT binding_NN of_IN LPS_NP to_TO CD14+_NP cells_NNS ._SENT As_IN expected_VBN ,_, when_WRB RAW_NP 264.7_CD cells_NNS were_VBD preincubated_VBN with_IN LPS_NP (_( 100_CD ng/ml_NNS )_) ,_, binding_VBG of_IN anti-CD14_NP MAb_NP 4C1_JJ (_( 50_CD ng/ml_NNS )_) to_TO the_DT cells_NNS was_VBD inhibited_VBN by_IN 40.2_CD %_NN +-_NN 11.9_CD %_NN (_( n_NN =_SYM 3_CD )_) ,_, suggesting_VBG that_IN the_DT epitope_NN ,_, which_WDT can_MD be_VB recognized_VBN by_IN MAb_NP 4C1_JJ ,_, is_VBZ located_VBN on_IN murine_JJ CD14_NP next_JJ to_TO the_DT LPS-binding_NP site_NN ._SENT Importantly_RB ,_, preincubation_NN with_IN 18-mer_NP LLKKK_NP or_CC 18-mer_NP LL_NP (_( 1_CD mug/ml_NN each_DT )_) inhibited_VBD the_DT binding_NN of_IN FITC-conjugated_NP anti-CD14_NP MAb_NP 4C1_JJ to_TO RAW_NP 264.7_CD cells_NNS by_IN 33.5_CD %_NN +-_NN 5.2_CD %_NN or_CC 26.2_CD %_NN +-_NN 9.8_CD %_NN ,_, respectively_RB (_( n_NN =_SYM 3_CD or_CC n_NN =_SYM 5_CD ;_: P_NN <_SYM 0.05_CD for_IN comparison_NN with_IN the_DT binding_NN of_IN FITC-conjugated_NP anti-CD14_NP MAb_NP 4C1_JJ in_IN the_DT absence_NN of_IN peptides_NNS )_) ,_, whereas_IN preincubation_NN with_IN 18-mer_NP K15-V32_NP or_CC LL-37_NP inhibited_VBD the_DT binding_NN by_IN only_RB 10_CD to_TO 14_CD %_NN ._SENT These_DT observations_NNS likely_RB suggest_VBP that_IN among_IN 18-mer_JJ peptides_NNS ,_, 18-mer_NP LLKKK_NP has_VBZ the_DT most_RBS potent_JJ activity_NN to_TO bind_VB to_TO CD14_NP near_IN the_DT LPS-binding_NP site_NN ,_, thereby_RB influencing_VBG the_DT binding_NN of_IN LPS_NP to_TO CD14_NP ._SENT Effects_NNS of_IN 18-mer_JJ peptides_NNS on_IN the_DT murine_JJ endotoxin_NN shock_NN model_NN ._SENT |_SYM Using_VBG d-galactosamine-sensitized_JJ mice_NNS ,_, we_PP assessed_VBD the_DT effects_NNS of_IN 18-mer_JJ peptides_NNS on_IN lethal_JJ LPS_NP activity_NN in_IN vivo_RB ._SENT d-Galactosamine_NP administration_NN sensitized_VBD mice_NNS to_TO the_DT lethal_JJ effect_NN of_IN LPS_NP ,_, and_CC 94_CD %_NN of_IN the_DT mice_NNS died_VBD within_IN 24_CD h_NN after_IN i.p._JJ injection_NN of_IN 200_CD ng_NNS of_IN LPS_NP ._SENT Notably_RB ,_, administration_NN of_IN 18-mer_NP K15-V32_NP ,_, 18-mer_NP LL_NP ,_, 18-mer_NP LLKKK_NP ,_, or_CC LL-37_JJ (_( 1_CD mug/mouse_NN )_) increased_VBD the_DT survival_NN rate_NN to_TO 33_CD ,_, 50_CD ,_, 67_CD ,_, or_CC 47_CD %_NN ,_, respectively_RB ,_, all_DT significantly_RB higher_JJR than_IN that_DT of_IN the_DT group_NN with_IN d-galactosamine_NP and_CC LPS_NP administration_NN alone_RB (_( P_NN <_SYM 0.05_CD )_) ;_: 18-mer_NP LLKKK_NP administration_NN was_VBD the_DT most_RBS protective_JJ ._SENT In_IN agreement_NN with_IN this_DT ,_, administration_NN of_IN an_DT 18-mer_JJ peptide_NN or_CC LL-37_JJ markedly_RB lowered_VBN the_DT LPS-induced_JJ increase_NN in_IN serum_NN TNF-alpha_NP levels_NNS (_( P_NN <_SYM 0.001_CD )_) ,_, and_CC 18-mer_NP LLKKK_NP had_VBD the_DT greatest_JJS effect_NN ._SENT In_IN addition_NN ,_, the_DT effects_NNS of_IN 18-mer_JJ peptides_NNS on_IN the_DT binding_NN of_IN FITC-conjugated_NP LPS_NP to_TO peritoneal_JJ macrophages_NNS (_( CD14+_NP cells_NNS )_) were_VBD analyzed_VBN by_IN flow_NN cytometry_NN ._SENT Administration_NN of_IN the_DT peptides_NNS ,_, especially_RB 18-mer_NP LLKKK_NP ,_, markedly_RB suppressed_VBD the_DT binding_NN of_IN FITC-conjugated_NP LPS_NP to_TO peritoneal_JJ macrophages_NNS (_( P_NN <_SYM 0.001_CD )_) ._SENT Concurrently_RB ,_, TNF-alpha_NP expression_NN in_IN peritoneal_JJ macrophages_NNS was_VBD investigated_VBN ._SENT Northern_JJ and_CC Western_JJ blot_NN analyses_NNS indicated_VBD that_DT administration_NN of_IN the_DT peptides_NNS ,_, particularly_RB 18-mer_NP LLKKK_NP ,_, strongly_RB suppressed_VBD LPS-induced_NP TNF-alpha_NP mRNA_NN and_CC protein_NN expression_NN by_IN peritoneal_JJ macrophages_NNS (_( data_NNS not_RB shown_VBN )_) ,_, just_RB as_RB was_VBD observed_VBN in_IN LPS-stimulated_JJ RAW_NP 264.7_CD cells_NNS ._SENT Together_RB ,_, these_DT observations_NNS likely_RB suggest_VBP that_IN among_IN 18-mer_JJ peptides_NNS ,_, 18-mer_NP LLKKK_NP exerts_VBZ the_DT most_RBS protective_JJ action_NN against_IN murine_JJ endotoxin_NN shock_NN by_IN blocking_VBG the_DT binding_NN of_IN LPS_NP to_TO CD14+_NP cells_NNS ,_, thereby_RB suppressing_VBG the_DT production_NN of_IN cytokines_NNS (_( such_JJ as_IN TNF-alpha_NP )_) by_IN these_DT cells_NNS ,_, possibly_RB via_IN its_PP$ potent_JJ binding_NN to_TO LPS_NP and_CC CD14_NP ._SENT FIG._NN 2_CD ._SENT |_SYM Effects_NN of_IN 18-mer_JJ peptides_NNS on_IN binding_VBG of_IN FITC-conjugated_NP LPS_NP to_TO RAW_NP 264_CD ._SENT Effects_NNS of_IN 18-mer_JJ peptides_NNS on_IN binding_VBG of_IN FITC-conjugated_NP LPS_NP to_TO RAW_NP 264.7_CD cells_NNS ._SENT (_( A_NP )_) RAW_NP 264.7_CD cells_NNS (_( 5_CD x_SYM 105/ml_JJ )_) were_VBD incubated_VBN with_IN 100_CD ng_NNS of_IN FITC-conjugated_NP LPS/ml_NP in_IN the_DT absence_NN or_CC presence_NN of_IN 5_CD mug_NN of_IN anti-LBP_NP MAb_NP 6G3_NP or_CC anti-CD14_NP MAb_NP 4C1/ml_NP in_IN RPMI_NP 1640_CD containing_VBG 10_CD %_NN FBS_NP for_IN 15_CD min_NN at_IN 37C_NP ._SENT (_( B_NP )_) Alternatively_RB ,_, RAW_NP 264.7_CD cells_NNS were_VBD incubated_VBN with_IN FITC-conjugated_NP LPS_NP in_IN the_DT presence_NN of_IN 1_CD mug_NN of_IN peptide_NN (_( 18-mer_NP K15-V32_NP ,_, 18-mer_NP LL_NP ,_, 18-mer_NP LLKKK_NP ,_, or_CC LL-37)/ml_NP in_IN RPMI_NP 1640_CD containing_VBG 10_CD %_NN FBS_NP ._SENT After_IN a_DT wash_NN ,_, the_DT binding_NN of_IN FITC-LPS_NP was_VBD analyzed_VBN by_IN flow_NN cytometry_NN ._SENT Background_NN (_( BG_NP )_) was_VBD assessed_VBN by_IN using_VBG RAW_NP 264.7_CD cells_NNS incubated_VBN without_IN FITC-LPS_NP ._SENT Data_NNS are_VBP from_IN one_CD of_IN five_CD separate_JJ experiments_NNS ._SENT FIG._NN 3_CD ._SENT |_SYM Dose-dependent_NP inhibition_NN of_IN the_DT binding_NN of_IN FITC-conjugated_NP LPS_NP to_TO RAW_NP 264_CD ._SENT Dose-dependent_JJ inhibition_NN of_IN the_DT binding_NN of_IN FITC-conjugated_NP LPS_NP to_TO RAW_NP 264.7_CD cells_NNS by_IN 18-mer_JJ peptides_NNS ._SENT RAW_JJ 264.7_CD cells_NNS (_( 5_CD x_SYM 105/ml_JJ )_) were_VBD incubated_VBN with_IN 100_CD ng_NNS of_IN FITC-conjugated_NP LPS/ml_NP in_IN the_DT absence_NN or_CC presence_NN of_IN 0.01_CD to_TO 10_CD mug_NN of_IN 18-mer_NP K15-V32_NP ,_, 18-mer_NP LL_NP ,_, 18-mer_NP LLKKK_NP ,_, or_CC LL-37/ml_NP in_IN RPMI_NP 1640_CD containing_VBG 10_CD %_NN FBS_NP for_IN 15_CD min_NN at_IN 37C_JJ ._SENT After_IN a_DT wash_NN ,_, the_DT binding_NN of_IN FITC-LPS_NP was_VBD analyzed_VBN by_IN flow_NN cytometry_NN ,_, and_CC median_JJ fluorescence_NN intensity_NN was_VBD determined_VBN ._SENT Binding_VBG of_IN LPS_NP was_VBD expressed_VBN as_IN a_DT percentage_NN of_IN that_DT obtained_VBN by_IN using_VBG RAW_NP 264.7_CD cells_NNS incubated_VBN with_IN FITC-conjugated_NP LPS_NP alone_RB ._SENT Data_NNS are_VBP means_VBZ +-_NN SD_NNS from_IN three_CD to_TO five_CD separate_JJ experiments_NNS ._SENT Values_NNS for_IN 18-mer_NP K15-V32_NP are_VBP compared_VBN with_IN those_DT for_IN 18-mer_NP LL_NP ,_, 18-mer_NP LLKKK_NP ,_, or_CC LL-37_JJ ._SENT *_SYM ,_, P_NN <_SYM 0.05_CD ;_: **_SYM ,_, P_NN <_SYM 0.01_CD ;_: ***_NN ,_, P_NN <_SYM 0.001_CD ._SENT FIG._NN 4_CD ._SENT |_SYM Effects_NN of_IN 18-mer_JJ peptides_NNS on_IN LPS-induced_NP TNF-alpha_NP expression_NN by_IN RAW_NP 264_CD ._SENT Effects_NNS of_IN 18-mer_JJ peptides_NNS on_IN LPS-induced_NP TNF-alpha_NP expression_NN by_IN RAW_NP 264.7_CD cells_NNS ._SENT RAW_JJ 264.7_CD cells_NNS (_( 106/well_NP in_IN a_DT 24-well_JJ microplate_NN )_) were_VBD incubated_VBN without_IN (_( Control_NP )_) or_CC with_IN 100_CD ng_NNS of_IN LPS/ml_NP in_IN the_DT absence_NN (_( LPS_NP )_) or_CC presence_NN of_IN 1_CD mug_NN of_IN peptide_NN (_( 18-mer_NP K15-V32_NP ,_, 18-mer_NP LL_NP ,_, 18-mer_NP LLKKK_NP ,_, or_CC LL-37)/ml_NP in_IN 500_CD mul_NN of_IN RPMI_NP 1640_CD containing_VBG 10_CD %_NN FBS_NP for_IN 4_CD h_NN at_IN 37C_JJ ._SENT After_IN incubation_NN ,_, cells_NNS were_VBD recovered_VBN ,_, and_CC expression_NN of_IN TNF-alpha_NP mRNA_NN and_CC protein_NN was_VBD analyzed_VBN by_IN Northern_NP (_( A_NP )_) and_CC Western_NP (_( B_NP )_) blotting_VBG ,_, respectively_RB ._SENT As_IN a_DT control_NN ,_, expression_NN of_IN beta-actin_NN mRNA_NN and_CC protein_NN was_VBD also_RB analyzed_VBN ._SENT Data_NNS are_VBP from_IN one_CD of_IN three_CD separate_JJ experiments_NNS ._SENT FIG._NN 5_CD ._SENT |_SYM Evaluation_NP of_IN LPS-binding_NP activities_NNS of_IN 18-mer_JJ peptides_NNS ._SENT Evaluation_NN of_IN LPS-binding_NP activities_NNS of_IN 18-mer_JJ peptides_NNS ._SENT (_( A_NP )_) LPS-binding_NP activities_NNS of_IN the_DT peptides_NNS were_VBD investigated_VBN by_IN incubating_VBG 0.02_CD to_TO 0.5_CD mug_NN of_IN 18-mer_NP K15-V32_NP ,_, 18-mer_NP LL_NP ,_, 18-mer_NP LLKKK_NP ,_, or_CC LL-37_JJ in_IN LPS-coated_NP 96-well_NP microtiter_NN plates_NNS (_( 100_CD ng_NNS of_IN LPS/well_NP )_) for_IN 1_CD h_NN at_IN 37C_JJ in_IN 50_CD mul_NN of_IN RPMI_NP 1640_CD ._SENT Bound_JJ peptides_NNS were_VBD detected_VBN by_IN TMB_NP reaction_NN by_IN using_VBG a_DT rabbit_NN anti-CAP18_NN Ab_NP and_CC HRP-conjugated_NP goat_NN anti-rabbit_NN IgG_NP ._SENT (_( B_LS )_) The_DT peptide_NN (_( 0.1_CD mug_NN of_IN either_DT 18-mer_NP K15-V32_NP ,_, 18-mer_NP LL_NP ,_, 18-mer_NP LLKKK_NP ,_, or_CC LL-37_JJ )_) was_VBD incubated_VBN in_IN LPS-coated_NP 96-well_NP microtiter_NN plates_NNS for_IN 1_CD h_NN at_IN 37C_JJ in_IN the_DT absence_NN or_CC presence_NN of_IN added_JJ LPS_NP (_( 0.05_CD to_TO 2.5_CD mug/well_NN )_) in_IN 50_CD mul_NN of_IN RPMI_NP 1640_CD ,_, and_CC bound_JJ peptides_NNS were_VBD detected_VBN as_IN described_VBN above_IN ._SENT Binding_VBG of_IN peptides_NNS to_TO LPS-coated_JJ plates_NNS was_VBD expressed_VBN as_IN a_DT percentage_NN of_IN that_WDT observed_VBD when_WRB 0.5_CD mug_NN (_( for_IN panel_NN A_DT )_) or_CC 0.1_CD mug_NN (_( for_IN panel_NN B_NN )_) of_IN each_DT peptide_NN was_VBD incubated_VBN in_IN the_DT absence_NN of_IN added_JJ LPS_NP ._SENT Data_NNS are_VBP means_VBZ +-_NN SD_NNS from_IN three_CD to_TO five_CD separate_JJ experiments_NNS ._SENT Values_NNS for_IN 18-mer_NP K15-V32_NP are_VBP compared_VBN with_IN those_DT for_IN 18-mer_NP LL_NP ,_, 18-mer_NP LLKKK_NP ,_, or_CC LL-37_JJ ._SENT *_SYM ,_, P_NN <_SYM 0.05_CD ;_: ***_NN ,_, P_NN <_SYM 0.001_CD ._SENT FIG._NN 6_CD ._SENT |_SYM Effects_NN of_IN 18-mer_JJ peptides_NNS on_IN the_DT interaction_NN of_IN LPS_NP with_IN LBP_NP ._SENT Effects_NNS of_IN 18-mer_JJ peptides_NNS on_IN the_DT interaction_NN of_IN LPS_NP with_IN LBP_NP ._SENT (_( A_NP )_) LPS-LBP_NP binding_NN was_VBD examined_VBN by_IN incubating_VBG 50_CD mul_NN of_IN RPMI_NP 1640_CD containing_VBG 0.1_CD ,_, 1_CD ,_, or_CC 10_CD %_NN FBS_NP in_IN LPS-coated_NP 96-well_NP microtiter_NN plates_NNS (_( 100_CD ng_NNS of_IN LPS/well_NP )_) for_IN 1_CD h_NN at_IN 37C_JJ ._SENT After_IN incubation_NN ,_, bound_VBN LBP_NP was_VBD detected_VBN by_IN TMB_NP reaction_NN using_VBG anti-LBP_NP MAb_NP 